Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
about
The combination of BH3-mimetic ABT-737 with the alkylating agent temozolomide induces strong synergistic killing of melanoma cells independent of p53Noncutaneous malignant melanoma: a prognostic model from a retrospective multicenter studyMetastatic melanoma - a review of current and future drugsHarnessing the cell death pathway for targeted cancer treatment.Metronomic chemotherapy for cancer treatment: a decade of clinical studies.Inhibition of angiogenesis for the treatment of metastatic melanoma.
P2860
Phase 2 trial of combination thalidomide plus temozolomide in patients with metastatic malignant melanoma: Southwest Oncology Group S0508.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Phase 2 trial of combination t ...... outhwest Oncology Group S0508.
@ast
Phase 2 trial of combination t ...... outhwest Oncology Group S0508.
@en
type
label
Phase 2 trial of combination t ...... outhwest Oncology Group S0508.
@ast
Phase 2 trial of combination t ...... outhwest Oncology Group S0508.
@en
prefLabel
Phase 2 trial of combination t ...... outhwest Oncology Group S0508.
@ast
Phase 2 trial of combination t ...... outhwest Oncology Group S0508.
@en
P2093
P2860
P356
P1433
P1476
Phase 2 trial of combination t ...... Southwest Oncology Group S0508
@en
P2093
Diane M Da Silva
James Moon
Jeffrey A Sosman
John A Thompson
Joseph I Clark
Laura F Hutchins
Lawrence E Flaherty
Vernon K Sondak
P2860
P304
P356
10.1002/CNCR.24739
P407
P50
P577
2010-01-01T00:00:00Z